- Home
- ADXN vs BOLT Comparison
ADXN vs BOLT Comparison
Compare ADXN & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | BOLT |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 10.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ADXN | BOLT |
|---|---|---|
| Price | $8.44 | $5.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 8.0K | ★ 26.4K |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $198,824.00 | ★ $5,195,000.00 |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $4.41 |
| 52 Week High | $12.05 | $12.60 |
Technical Indicators
Market Signals| Indicator | ADXN | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 56.59 |
| Support Level | $7.47 | $5.09 |
| Resistance Level | $8.30 | $5.64 |
| Average True Range (ATR) | 0.45 | 0.39 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 72.22 | 55.20 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.